SQI Diagnostics (SQI Diagnostics) EPS (Basic) : $-0.04 (TTM As of Mar. 2023)

View and export this data going back to 2009. Start your Free Trial

What is SQI Diagnostics EPS (Basic)?

SQI Diagnostics's basic earnings per share (Basic EPS) for the three months ended in Mar. 2023 was $-0.01. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.04.

SQI Diagnostics's EPS (Diluted) for the three months ended in Mar. 2023 was $-0.01. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2023 was $-0.04.

SQI Diagnostics's EPS without NRI for the three months ended in Mar. 2023 was $-0.01. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2023 was -0.04.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

SQI Diagnostics EPS (Basic) Historical Data

The historical data trend for SQI Diagnostics's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

SQI Diagnostics EPS (Basic) Chart

SQI Diagnostics Annual Data

Trend

Sep13

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

EPS (Basic)

Get a 7-Day Free Trial

-0.05

-0.03

-0.02

-0.04

SQI Diagnostics Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
EPS (Basic)	Get a 7-Day Free Trial															-0.01	-0.01	-0.02	-0.01	-0.01

SQI Diagnostics EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

SQI Diagnostics's Basic EPS for the fiscal year that ended in Sep. 2022 is calculated as

Basic EPS (A: Sep. 2022 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-13.886	-	0)	/	389.720
	=	-0.04

SQI Diagnostics's Basic EPS for the quarter that ended in Mar. 2023 is calculated as

Basic EPS (Q: Mar. 2023 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Basic Average)
	=	(-2.592	-	0)	/	406.246
	=	-0.01

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.04

SQI Diagnostics (OTCPK:SQIDF) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

SQI Diagnostics EPS (Basic) Related Terms

Thank you for viewing the detailed overview of SQI Diagnostics's EPS (Basic) provided by GuruFocus.com. Please click on the following links to see related term pages.

SQI Diagnostics (SQI Diagnostics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » SQI Diagnostics Inc (OTCPK:SQIDF) » Definitions » EPS (Basic)

Comparable Companies

Traded in Other Exchanges

N/A

Address

36 Meteor Drive, Toronto, ON, CAN, M9W 1A4

Website

https://www.sqidiagnostics.com

SQI Diagnostics Inc is the leader in the field of lung health. The company develops and manufactures respiratory health and precision medicine tests that run on SQI's automated systems. The company is developing tests to simplify and improve COVID-19 antibody monitoring, rapid acute lung injury testing, donor organ transplant informatics, and immunological protein and antibody testing. Its geographical segments are the United States, Canada, and Europe. Canada accounts for more than half of its revenues.